Effect of rituximab on a salivary gland ultrasound score in primary Sjögren’s syndrome: results of the TRACTISS randomised double-blind multicentre substudy

OBJECTIVES: To compare the effects of rituximab versus placebo on salivary gland ultrasound (SGUS) in primary Sjögren’s syndrome (PSS) in a multicentre, multiobserver phase III trial substudy. METHODS: Subjects consenting to SGUS were randomised to rituximab or placebo given at weeks 0, 2, 24 and 26...

Descripción completa

Detalles Bibliográficos
Autores principales: Fisher, Benjamin A, Everett, Colin C, Rout, John, O’Dwyer, John L, Emery, Paul, Pitzalis, Costantino, Ng, Wan-Fai, Carr, Andrew, Pease, Colin T, Price, Elizabeth J, Sutcliffe, Nurhan, Makdissi, Jimmy, Tappuni, Anwar R, Gendi, Nagui S T, Hall, Frances C, Ruddock, Sharon P, Fernandez, Catherine, Hulme, Claire T, Davies, Kevin A, Edwards, Christopher John, Lanyon, Peter C, Moots, Robert J, Roussou, Euthalia, Richards, Andrea, Sharples, Linda D, Bombardieri, Michele, Bowman, Simon J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867400/
https://www.ncbi.nlm.nih.gov/pubmed/29275334
http://dx.doi.org/10.1136/annrheumdis-2017-212268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867400/
https://www.ncbi.nlm.nih.gov/pubmed/29275334
http://dx.doi.org/10.1136/annrheumdis-2017-212268

Ejemplares similares